Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 apr 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Charles River Laboratories and Galapagos complete transaction
Bericht
Mechelen, Belgium; 1 April 2014 - Galapagos NV (Euronext: GLPG) confirms the completion of the transaction announced on 13 March 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to €134 million.
All closing conditions of the definitive agreement have been met, and Charles River is now integrating the BioFocus and Argenta operations into its organization. The purchase price was €129 million in cash, subject to certain post-closing working capital adjustments. Galapagos has received this €129 million payment and today has a cash balance of approximately €248 million. Galapagos is eligible to receive a €5 million earnout payment after 12 months, upon achievement of a revenue target for the divested service division.
Datum laatste update: 25 maart 2026